Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Oncology InstituteTOIIW 56 1-Year Share Buyback Ratio is -12.40 as of Mar. 2026. GuruFocus rates TOIIW with a GF Score™ of 56/100. The stock has 4 warning signs investors should review. Among 385 Healthcare Providers & Services companies, The Oncology Institute ranks worse than 74.55% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. The Oncology Institute's current 1-Year Share Buyback Ratio was -12.40%.
TOIIW's 1-Year Share Buyback Ratio is ranked worse than 74.55% of 385
companies
in the Healthcare Providers & Services industry
Industry Median: -1
vs TOIIW: -12.40
The Oncology Institute (NAS:TOIIW) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
The Oncology Institute 1-Year Share Buyback Ratio Related Terms
TOIIW vs SRTA, CCRN, CYH: 1-Year Share Buyback Ratio Comparison
For the Medical Care Facilities subindustry, The Oncology Institute's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute 1-Year Share Buyback Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -12.40 mean?
The Oncology Institute (TOIIW) has a 1-Year Share Buyback Ratio of -12.40 as of Mar. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for The Oncology Institute and its competitors. According to the industry distribution chart, The Oncology Institute ranks #287 out of 385 companies in the Healthcare Providers & Services industry, placing it in the top 74.5%.
Is The Oncology Institute's 1-Year Share Buyback Ratio too high?
The Oncology Institute's current 1-Year Share Buyback Ratio is -12.40. Based on the distribution chart, The Oncology Institute ranks #287 out of 385 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, The Oncology Institute has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's 1-Year Share Buyback Ratio compare to SRTA and CCRN?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #287 out of 385 companies for 1-Year Share Buyback Ratio. This places The Oncology Institute in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Healthcare Providers & Services company?
A good 1-Year Share Buyback Ratio depends on the Healthcare Providers & Services industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for The Oncology Institute and its competitors. The Oncology Institute's current 1-Year Share Buyback Ratio is -12.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current 1-Year Share Buyback Ratio of -12.40. The current 1-Year Share Buyback Ratio is -12.40. The Oncology Institute's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current 1-Year Share Buyback Ratio is -12.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for TOIIW
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOIIW has been successfully added to your 
